Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment
(WorldNews Germany)

Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline Holzkirchen, November 12, 2019 - Sandoz, a Novartis division and a global leader in biosimilars, presented an interim analysis (abstract number 553) from the COMPACT study on real-world treatment of rheumatic disease patients with biosimilar Erelzi® (etanercept-szzs)...